Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 978-984

  Dong, Zhongyun ^a   Meller, Jaroslaw ^a   Succop, Paul ^a   Wang, Jiang ^a   Wikenheiser Brokamp, Kathryn ^a   Starnes, Sandra ^a   Lu, Shan ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

HER HER2 elicited signaling pathway; Ligand; Lung cancer; NF B; Secretory phospholipase A2 IIa

Indexed keywords

BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 IIA; TUMOR MARKER; UNCLASSIFIED DRUG; VARESPLADIB; ERBB2 PROTEIN, HUMAN; NEU DIFFERENTIATION FACTOR; NF-KAPPA B KINASE; NRG1 PROTEIN, HUMAN; PHOSPHOLIPASE A2 GROUP II; PLA2G2A PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; ENZYME STRUCTURE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR DOCKING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; BLOOD; CELL LINE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; CELL LINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP II PHOSPHOLIPASES A2; HUMANS; LUNG NEOPLASMS; MOLECULAR DOCKING SIMULATION; NEUREGULIN-1; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84904399684     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2486     Document Type: Article

References (49)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7): vii56-vii64, 2012.
3. Gridelli C, Ardizzoni A, Douillard JY, et al: Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 68: 319-331, 2010.
4. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25: 5506-5518, 2007. (Pubitemid 350232227)
5. Goffin J, Lacchetti C, Ellis PM, Ung YC and Evans WK: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274, 2010.
6. Cataldo V D, Gibbons D L, Perez-Soler R a nd Quintas-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Engl J Med 364: 947-955, 2011.
7. Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 29: 37-48, 2010.
8. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. New Engl J Med 353: 133-144, 2005. (Pubitemid 41058345)
9. Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59: 752-757, 2007. (Pubitemid 351412076)
10. Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6: 350-354, 2006. (Pubitemid 44026037)
11. Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest 136: 260-271, 2009.
12. Henschke CI, McCauley DI, Yankelevitz DF, et al: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354: 99-105, 1999. (Pubitemid 29313143)
13. Wahidi MM, Govert JA, Goudar RK, Gould MK and McCrory DC: Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 94S-107S, 2007. (Pubitemid 47502802)
14. Starnes SL, Reed MF, Meyer CA, et al: Lung cancer screening with low-dose CT in an area endemic for Histoplasma Capsulatum: minimizing invasive procedures for benign nodules. J Thorac Cardiovasc Surg 141: 688-693, 2011.
15. Team TNLSTR: Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med 365: 395-409, 2011.
16. Lederle FA and Niewoehner DE: Lung cancer surgery. A critical review of the evidence. Arch Intern Med 154: 2397-2400, 1994. (Pubitemid 24348149)
17. Cummings BS: Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 74: 949-959, 2007.
18. Lambeau G and Lazdunski M: Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci 20: 162-170, 1999.
19. Antonio V, Brouillet A, Janvier B, et al: Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. Biochem J 368: 415-424, 2002. (Pubitemid 35454520)
20. Dong Z, Liu Y, Scott KF, et al: Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis 31: 1948-1955, 2010.
21. Triggiani M, Granata F, Giannattasio G and Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. Journal Allergy Clin Immunol 116: 1000-1006, 2005. (Pubitemid 41571779)
22. Meyer AM, Dwyer-Nield LD, Hurteau GJ, et al: Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25: 1517-1524, 2004. (Pubitemid 39162717)
23. Kupert E, Anderson M, Liu Y, et al: Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer 11: 513, 2011.
24. Lu S, Tsai SY and Tsai MJ: Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140: 5054-5059, 1999.
25. Oleksowicz L, Liu Y, Bracken RB, et al: Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and potential plasma biomarker for poor prognosis of prostate cancer. Prostate 72: 1140-1149, 2012.
26. Schulze WX, Deng L and Mann M: Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008, 2005.
27. Hsieh AC and Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97: 453-457, 2007. (Pubitemid 47258458)
28. Lovly CM and Carbone DP: Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol 8: 68-70, 2011.
29. Davies AM, Lara PN Jr, Mack PC and Gandara DR: Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13: s4647-s4651, 2007.
30. Engelman JA and Cantley LC: The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: 4372s-4376s, 2006. (Pubitemid 44197184)
31. Tas SW, Vervoordeldonk MJ and Tak PP: Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 9: 160-170, 2009.
32. Escobar M, Velez M, Belalcazar A, Santos ES and Raez LE: The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol 2011: 806506, 2011.
33. Sved P, Scott KF, McLeod D, et al: Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 64: 6934-6940, 2004. (Pubitemid 39331002)
34. Patel MI, Singh J, Niknami M, et al: Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res 14: 8070-8079, 2008.
35. Belinsky GS, Rajan TV, Saria EA, Giardina C and Rosenberg DW: Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog 46: 106-116, 2007.
36. Mulherkar R, Kirtane BM, Ramchandani A, Mansukhani NP, Kannan S and Naresh KN: Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis. Oncogene 22: 1936-1944, 2003. (Pubitemid 36523631)
37. Hernandez M, Martin R, Garcia-Cubillas MD, Maeso-Hernandez P and Nieto ML: Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol 12: 1014-1023, 2010.
38. Martin R, Hernandez M, Ibeas E, et al: Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells. J Neurochem 111: 988-999, 2009.
39. Narayanan BA, Narayanan NK, Pittman B and Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10: 7727-7737, 2004. (Pubitemid 39557538)
40. Kobayashi N, Barnard RJ, Henning SM, et al: Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 12: 4662-4670, 2006. (Pubitemid 44297819)
41. Dong Z, Liu Y, Levin L, Oleksowicz L, Wang J and Lu S: Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncol Rep 25: 1511-1516, 2011.
42. Granata F, Frattini A, Loffredo S, et al: Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 184: 5232-5241, 2010.
43. Baek SH, Lim JH, Park DW, et al: Group IIA secretory phospholipase A(2) stimulates inducible nitric oxide synthase expression via ERK and NF-kappaB in macrophages. Eur J Immunol 31: 2709-2717, 2001.
44. Park DW, Kim JR, Kim SY, et al: Akt as a mediator of secretory phospholipase A2 receptor-involved inducible nitric oxide synthase expression. J Immunol 170: 2093-2099, 2003.
45. Ibeas E, Fuentes L, Martin R, Hernandez M and Nieto ML: Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK. Biochim Biophys Acta 1793: 1837-1847, 2009.
46. Scott KF, Sajinovic M, Hein J, et al: Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 92: 601-610, 2010.
47. Valentin E and Lambeau G: Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta 1488: 59-70, 2000.
48. Hernandez M, Burillo SL, Crespo MS and Nieto ML: Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem 273: 606-612, 1998. (Pubitemid 28042251)
49. Yu JA, Mauchley D, Li H, et al: Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg 144: 1185-1191, 2012.